Keyword: Bydureon

In a busy week at the European Commission, Novartis’ Kymriah, Gilead’s Yescarta, Jazz's Vyxeos, Alnylam's Onpattro and others got approvals.

Novo Nordisk debuted its first DTC campaign for Type 2 diabetes drug Ozempic this week, setting the promotional stage for its aspiring blockbuster.

At ADA, an AstraZeneca executive said he's "very optimistic" about the company's cardiovascular outcomes study for Farxiga.

Patients on Trulicity were more likely to continue therapy after a year than those on rival meds, according to data presented at ADA.

Novo Nordisk has secured 2018 formulary coverage for Ozempic from leading U.S. pharmacy benefit manager Express Scripts.

AstraZeneca is hoping a new formulation of Bydureon will give the med some competitive firepower against a field of tough rivals.

Anyone looking for a heart-helping class effect from GLP-1 diabetes meds wouldn't be encouraged by the Bydureon data AstraZeneca rolled out Thursday.

Pay-for-performance deals have been gaining popularity among drugmakers, and Harvard Pilgrim has been ready and willing to strike up partnerships. The latest to do so? AstraZeneca.

AstraZeneca finally has cardiovascular outcomes data for one of its top diabetes contenders. But the new results don’t measure up to rivals' studies.